Biogen pulls Alzheimer’s drug application in Europe as EMA calls data insufficient

 
The struggles for Biogen Alzheimer’s drug extend beyond the U.S. The drugmaker’s efforts to get the European Medicines Agency to reconsider their opinion of Aduhelm has been unsuccessful, leading the company to withdraw its application seeking European marketing authorization.
Biogen…

Source: medcitynews.com – Read more